Wednesday, July 8, 2026

Patent intelligence · US

US 11844764

Agitation process for preparing a carbetocin drug product

granted A61KA61K38/095A61K47/22A61K47/26
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 17
Applicant portfolio 77
Patent details — US 11844764
Jurisdiction
US
Status
granted
Grant date
Dec 19, 2023
Expiration
Dec 14, 2043
Claims
9
CPC classes
A61K, A61K38/095, A61K47/22, A61K47/26
View on Google Patents ↗

Quick answer

US 11844764 (Agitation process for preparing a carbetocin drug product) is held by ACADIA Pharmaceuticals Inc.. Status: granted. Granted Dec 19, 2023. Expires Dec 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
9
CPC classes
A61K, A61K38/095, A61K47/22, A61K47/26, A61K47/38, A61K9/08

More from ACADIA Pharmaceuticals Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11827600

    Crystalline forms of trofinetide

    ACADIA Pharmaceuticals Inc. · Expires Nov 23, 2043

    granted
  2. US 11464768

    Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis

    ACADIA Pharmaceuticals Inc. · Expires Oct 6, 2042

    granted
  3. US 11452721

    Formulations of pimavanserin

    ACADIA Pharmaceuticals Inc. · Expires Sep 22, 2042

    granted
  4. US 11191757

    Combination of pimavanserin and cytochrome P450 modulators

    ACADIA Pharmaceuticals Inc. · Expires Dec 2, 2041

    granted
  5. US 11161826

    Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

    ACADIA Pharmaceuticals Inc. · Expires Oct 28, 2041

    granted
  6. US 11135211

    Pimavanserin for treating impulse control disorder

    ACADIA Pharmaceuticals Inc. · Expires Sep 30, 2041

    granted
  7. US 11091473

    Compounds for pain treatment, compositions comprising same, and methods of using same

    ACADIA Pharmaceuticals Inc. · Expires Aug 12, 2041

    granted

Frequently asked questions

What is US patent 11844764?

US 11844764 (Agitation process for preparing a carbetocin drug product) is held by ACADIA Pharmaceuticals Inc.. Status: granted. Granted Dec 19, 2023. Expires Dec 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11844764?

ACADIA Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 77 pharmaceutical patents for this assignee.

When does US 11844764 expire?

Our index shows an expiration date of Dec 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.